EGFR and non-small cell lung carcinoma: Gefitinib and erlotinib are the first-generation anti-EGFR TKIs that were first studied in advanced non-small cell lung cancer and later, for the first time, outperformed chemotherapy in the first-line treatment of EGFR-mutated NSCLC [9].